DAPT, gamma-Secretase inhibitor (ab120633)
Key features and details
- γ-Secretase inhibitor
- CAS Number: 208255-80-5
- Purity: > 99%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
DAPT, gamma-Secretase inhibitor -
Description
γ-Secretase inhibitor -
Biological description
γ-Secretase inhibitor. Inhibits Notch signalling in vitro. Inhibits total Aβ and Aβ42 production in human primary cultures (IC50 values are 115 and 200 nM, respectively) with no effect on APPα and APPβ levels. Blood-brain barrier permeable. 3D Growth matrix component and component of cerebral organoid differentiation media.
-
Purity
> 99% -
CAS Number
208255-80-5 -
Chemical structure
Properties
-
Chemical name
N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)-phenylglycine t-butyl ester -
Molecular weight
432.47 -
Molecular formula
C23H26F2N2O4 -
PubChem identifier
5311272 -
Storage instructions
Store at +4°C. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C[C@@H](C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC(C)(C)C)NC(=O)CC2=CC(=CC(=C2)F)F -
Source
Synthetic
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120633 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Images
-
Chemical Structure - DAPT, gamma-Secretase inhibitor (ab120633)2D chemical structure image of ab120633, DAPT, gamma-Secretase inhibitor
-
Functional Studies - DAPT, gamma-Secretase inhibitor (ab120633)ab81283 staining AKT1 (phospho S473) in MCF7 cells treated with DAPT (ab120633), by ICC/IF. Decrease in expression of AKT1 (phospho S473) correlates with increased concentration of DAPT, as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120633 (DAPT) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab81283 (1/200 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue. -
Functional Studies - DAPT, gamma-Secretase inhibitor (ab120633)This image is courtesy of an Abreview submitted by a verified customerKc167 cells were treated with varying concentrations of DAPT (ab120633) in DMSO for 16hr at 25°C; DMSO only was used as the negative control. The cells were further incubated for 30 minutes with 4mM EGTA in PBS (in the presence of DAPT), and were then lysed for analysis. To measure Notch activity, Notch targets E(spl)mβ-HLH and E(spl)m3-HLH mRNA levels were assayed. Data shows the fold change of mRNA levels of E(spl)mβ-HLH and E(spl)m3-HLH under different conditions, normalised to DMSO treatment (negative control). Notch activation by EGTA is abrogated by treatment with DAPT.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (19)
ab120633 has been referenced in 19 publications.
- Fukusumi H et al. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. FEBS Open Bio 11:354-366 (2021). PubMed: 33301617
- Tan LS et al. Protocol for the generation of pancreatic and hepatic progenitors from human pluripotent stem cells for gene regulatory assays. STAR Protoc 2:100471 (2021). PubMed: 33997805
- Zhan C et al. Effect of the Notch4/Dll4 signaling pathway in early gestational intrauterine infection on lung development. Exp Ther Med 22:972 (2021). PubMed: 34335914
- Li K et al. M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. J Exp Clin Cancer Res 40:325 (2021). PubMed: 34656164
- Wei H et al. Up-regulation of miR-139-5p protects diabetic mice from liver tissue damage and oxidative stress through inhibiting Notch signaling pathway. Acta Biochim Biophys Sin (Shanghai) 52:390-400 (2020). PubMed: 32293663
